Craniopharyngioma and Pregnancies

Key facts

Sponsor

Assistance Publique - Hôpitaux de Paris

Principal Investigator

Anne BACHELOT, MD, PhD, DO

Assistance Publique - Hôpitaux de Paris

Intervention

Questionnaire(other)

Enrollment

100 enrolled

Eligibility

18 years · FEMALE

Timeline

2025 – 2026

Study locations (1)

• Pitié-Salpêtrière hospital, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Craniopharyngioma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07177482
  ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
  Deling Li
• RECRUITINGPHASE2NCT05525273
  Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
  Eva Marie Erfurth, MD, PhD
• RECRUITINGPHASE2NCT05465174
  Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
  Sabine Mueller, MD, PhD
• ENROLLING BY INVITATIONNCT03610906
  Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
  University of Colorado, Denver
• ACTIVE NOT RECRUITINGPHASE2NCT03224767
  Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
  Alliance for Clinical Trials in Oncology
• ACTIVE NOT RECRUITINGPHASE2NCT02792582
  A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
  St. Jude Children's Research Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT01419067
  A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection
  St. Jude Children's Research Hospital

See all trials for Craniopharyngioma →